|
HLL to venture into vaccine manufacturing, sets
sales target of Rs.1000 cr by 2010
Hindustan Latex Limited (HLL), the largest contraceptive manufacturing PSU in
the country, is venturing into manufacturing and marketing of vaccines,
nutraceuticals and natural products segments within a year with an objective of
achieving a sales target of Rs 1000 crore turnover by 2010.
The company, which has already announced its foray into vaccines marketing with
two products to be launched soon, is on an anvil to set up a vaccine division by
the year 2007 by adding more products in the list. The company is also probing
opportunities to launch a vaccines manufacturing plant as the third phase of the
project. The first phase will focus on marketing products from other companies
while the second phase would deal with adding more products into the portfolio
with launching a separate vaccines division, according to the company sources.
As an initial stage, the company has already tied up with the Bharat Biotech
International Ltd., Hyderabad, to market Hepatitis B and Typhoid vaccines the
country by November 2006 and an official has taken charge to look after the
vaccine market and projects. By setting up the vaccine manufacturing plant,
probably at Belgaum, Karnataka, or in the outskirts of Chennai, the company will
deal with production and marketing of Rabbies Vaccines, tetravalent and
pentavalent vaccines, added sources.
The marketing activities on vaccine products would be handled by the women's
health division in the initial stage and will set as a separate division by
2007-08 with its marketing headquarters at Chennai, added sources to Pharmabiz.
The company has recently marketed Rs 11 crore vaccine for Japanese Encephalitis
in tie up with Bharat Biotech.
HLL's foray into natural products segment in collaboration with major Ayurveda
drug manufacturing companies is expected to hit the market within six months.
The venture will be triggered by introducing Galactagogue, a drug to enhance
milk secrition of lactating mother and two products for topical pain leaving, a
linament for joint pain and a gel for mascular pain in women due to calcium
deficiency.
The company is also evaluating chances to introduce baby-food based on banana,
arrow root and raagi in its freshly coming up Nutraceutical division, envisaged
to finalise the product portfolio within eight months, according to P N Menon,
head of women's health care pharma division and National Sales Manager (New
Products), HLL.
The women's health care pharma division, launched in 2005, is also planning to
introduce 10 new products in each six months. "Our mission is to enter into all
the therapeutic areas, which have a market potential of more than Rs 10 crore
for a particular area, related to women's healthcare," Menon told Pharmabiz.
The division will launch Petogen, a contraceptive depot injection to be used
once in three months, imported from Fresenius, Germany, by the month of October.
The company has signed for marketing rights for 20 years for the depot medroxy
progesterone, worth Rs 150 per injection, and expects a Rs One crore ethical
market for the product in the country, he added.
(Ref : Chronicle Pharmabiz dated October 12, 2006)
India, China To Account For 25 Percent Global Analytical
Equipment Market By 2007
The analytical instrument market in India and China are growing around 11per
cent in the last few years and these two countries are likely to share around 20
to 25 per cent of the global market by 2007, according to S Thyagarajan, vice
president, Indian Analytical Instruments Association (IAIA) and managing
director, Spinco Biotech Pvt Ltd.
Quoting the industry newsletter, Instrumental, he noted that the domestic
manufacturers account for only 15 per cent of the USD 100 billion potential of
Indian analytical instruments market. It is estimated that the markets of India
and China will jointly offer about 40 per cent growth for Mettler Toledo
International Inc., US, 36 per cent growth for Thermo Electron Corporation, US,
24 per cent growth for Varian Analytical Instruments Ltd., UK and 20 per cent
growth for Dionex Corporation, US by 2007.
The Indian players will have to compete with these international companies,
which have set benchmarks in standard, quality and size. India had imported
analytical instruments worth around 644 million Euro in a total of 1000 million
Euro in 2003-04. During the same period, India exported 35 million Euro worth
analytical instruments mainly to the African, Middle East and other Asian
markets. The country also maintained an 11 per cent growth, equal to the growth
of the analytical market in China. If the Indian players have a focused strategy
for the next five or six years, the country could record better growth in the
field, said Thyagarajan, while attending a press conference to announce the
Analytica-Anacon 2006.
He noted that now the international companies are also setting up manufacturing
plants in India, instead of their Indian subsidiaries, which were marketing in
India. But in China, these companies had set up manufacturing plants.
According to IAIA and International Exhibition and Fair Services Ltd., Germany,
the Analytica-Anacon 2006, the international trade fair and conference for
analytical instrumentation, biotechnology, laboratory technology and services
will be held at Banglore from 16 to 18, November, 2006. The exhibition is
envisaged to provide update on technical and innovative information on the
industry from the experts of various top ranked analytical instrument R&D
experts, from which India can hold the spirit to play a better role in the USD
32 billion global analytical instruments industry, according to the organizers.
(Ref : Chronicle Pharmabiz dated October 12, 2006)
|
